Pfizer Ventures could be in line for an exit after AbbVie purchased a buyout option for Parkinson's disease drug developer Mitokinin.

Mitokinin, a US-based neurodegenerative disease drug developer backed by Pfizer, sold an exclusive buyout option to another pharmaceutical firm, AbbVie, on Tuesday. AbbVie made an upfront payment of undisclosed size for the right to acquire Mitokinin once it has completed investigational new drug-enabling studies for its lead asset, a potential therapy for Parkinson’s disease for…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.